Loading
companiesCompany
BioLineRx
BioLineRx is an Israeli company whose CXCR4 inhibitor motixafortide (Aphexda) was approved in the United States in 2023 to mobilise stem cells for autologous transplant in multiple myeloma, and which tests the drug with pembrolizumab in pancreatic cancer.
Also called: BioLineRx, Ltd.BioLineRx Ltd.
Overview
BioLineRx, based in Modi'in and listed on Nasdaq and Tel Aviv, develops motixafortide (BL-8040), a long-acting CXCR4 antagonist. In the phase 3 GENESIS trial a single dose with filgrastim mobilised enough stem cells for transplant in far more myeloma patients than filgrastim alone, leading to FDA approval as Aphexda in September 2023; US commercial rights were licensed to Ayrmid in 2024. The company also studies motixafortide with pembrolizumab and chemotherapy in metastatic pancreatic cancer and for sickle cell gene therapy mobilisation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Modi'in, IL
Scorecard
All companies#41of 1244 companies, score 77
- approved products +18
- targets +2
- modalities +6
- regions +7
- 24-month regulatory events +14
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 1 targets, 3,305 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
ApprovedRecombinant granulocyte colony-stimulating factor
Filgrastim (G-CSF) · Neupogen
Filgrastim (Neupogen and its biosimilars) is a daily injection that speeds the recovery of infection-fighting white cells after chemotherapy, lets doctors give chemotherapy on schedule and mobilises stem cells for transplant.
ApprovedCXCR4 antagonist peptide, subcutaneous injection
Motixafortide · Aphexda
Motixafortide is an injection given with G-CSF before stem cell collection in people with multiple myeloma, approved in the United States in 2023, so that enough stem cells for an autologous transplant can be harvested in one or two sessions.
Similar pages
- TrialMobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Shares Motixafortide, Filgrastim (G-CSF), Multiple myeloma.
- TreatmentPlerixafor
Shares Motixafortide, CXCR4, Filgrastim (G-CSF), Multiple myeloma.
- TrialFilgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
Shares Filgrastim (G-CSF), Multiple myeloma.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
Shares Filgrastim (G-CSF), Pembrolizumab.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
Shares Filgrastim (G-CSF), Pembrolizumab.
- Key paperTargeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Shares CXCR4, Pancreatic ductal adenocarcinoma.
- TechnologyGrowth factors: G-CSF and febrile neutropenia prevention
Shares A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl, Filgrastim (G-CSF).
- TermVRd and Dara-VRd (myeloma induction regimens)
Shares Autologous stem cell transplant (ASCT), Multiple myeloma.
cancers
fronts
targets
drugs
ApprovedRecombinant granulocyte colony-stimulating factor
Filgrastim (G-CSF) · Neupogen
ApprovedCXCR4 antagonist peptide, subcutaneous injection
Motixafortide · Aphexda
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)